In view of the biological activity of nicotinamide mononucleotide
, the development of drugs with nicotinamide mononucleotide as an active ingredient has become a medical hotspot. The CAS number of the NMN
is 1094-61-7. Huizenga of the United States invented a group of compositions containing active ingredients such as NAD+, NMN, NR, etc., which are useful for anti-aging and antioxidant treatments. Akihiro et al. of Yoshida University invented NMN and NR and its salts as raw materials for the treatment of corneal disorders. Imai of the University of Washington has developed treatments to improve age-related obesity, hyperlipidemia, type 2 diabetes, and drugs that use NMN as an active ingredient. Douglas et al. invented a method for evaluating and treating vascular endothelial disorders and a drug using NMN as an active ingredient. Michael et al. developed a NMN modulator (a neuroprotective drug) that can be used to treat neurodegenerative diseases.